HD Labs Tirzepatide 30 mg – GIP/GLP-1 Dual-Agonist Injection
Advanced Metabolic • Weight-Management • Glycaemic Control Therapy
HD Labs Tirzepatide 30 mg is a dual-acting GIP and GLP-1 receptor agonist presented as a pre-filled subcutaneous injection pen. Tirzepatide is clinically recognised for its role in appetite regulation, glucose control, and metabolic optimisation, making it a leading option in modern metabolic and weight-management treatment protocols.
By targeting both GIP and GLP-1 pathways, Tirzepatide offers a more comprehensive metabolic signalling approach compared to single-pathway GLP-1 therapies.
Key Therapeutic Focus
Appetite suppression and satiety signalling
Weight-management support
Blood glucose regulation
Improved metabolic efficiency
Reduced caloric intake through central appetite control
Product Information
Active Ingredient: Tirzepatide
Strength: 30 mg
Mechanism: Dual GIP / GLP-1 receptor agonist
Form: Solution for injection
Delivery: Pre-filled pen
Administration Route: Subcutaneous injection
Use: Single-patient use only
Quality & Manufacturing
Pharmaceutical-grade formulation
Precision-filled injection system
Designed for stability, accuracy, and ease of use
Manufactured under controlled quality standards